The Danish pharma bought the nonsteroidal mineralocorticoid receptor antagonist, called ocedurenone, from KBP Biosciences a ...

Finerenone—a selective non-steroidal mineralocorticoid receptor antagonist—has been shown to have kidney protective effects in individuals with chronic kidney disease (CKD) with type 2 ...

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...

including action on the mineralocorticoid receptors in the kidneys. It plays a central role in the regulation of blood pressure.

New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone are summarized in a short video.

Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented ...

Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

The oral, non-steroidal mineralocorticoid receptor (MR) antagonist has been approved as Kerendia in the US – its first world market – to reduce the risk of kidney function decline, kidney ...